Commercial cell lines perform robustly under many experimental conditions and exhibit hallmark molecular aspects of PDA (e.g. KRAS and TP53 mutations), thereby functioning as convenient model systems; yet, their generalizability to primary and metastatic PDAs in patients is difficult to determine [64, 65]. This evidence concerns the gene KRAS and Patent ductus arteriosus.